Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients.

3104 Background: Oncolytic viruses preferentially replicate in, and kill cancerous cells. Wild-type reovirus is a proprietary isolate of reovirus type 3 Dearing, a double-stranded RNA human reovirus. In two trials using intralesional administration in gliomas and recurrent brain tumours, wild-type reovirus has been well tolerated, with early signs of efficacy. A recently completed trial in Leeds, UK (Adair et al. 2012 Sci Transl Med) has proven that intravenous wild-type reovirus accesses colorectal cancer liver metastases. Intravenous delivery to brain tumours would be easier, cheaper and more acceptable to patients than intralesional administration. To date, no oncolytic virus has been shown to infect brain tumours following intravenous delivery. This trial aims to identify whether wild-type reovirus can cross the blood brain barrier and infect brain tumours following intravenous administration. Methods: This is an open-label, non-randomised, single centre study of intravenous wild-type reovirus adminis...